Chengdu Baiyu new drug ginkgolide injection production project officially opened

In 2013, Sun Yi, chairman and President of Chengdu Baiyu group, had a really good life Since the company's innovative drug ginkgolide injection, which has been independently researched and developed for 11 years, was approved to be listed at the end of 2011, good news came one after another: more than 200 investment institutions took the initiative to seek cooperation at home, and the production project of ginkgolide injection (used to treat ischemic stroke), a wholly-owned subsidiary of Chengdu Baiyu jingelei Pharmaceutical Co., Ltd., was officially opened on December 22, and entered the "little giant" of Chengdu Enterprise project library "One good thing after another, when the new base is put into production, the output value of the company will be doubled." Describing the company's future, Sun Yi said, "our efforts in the past few years have not been in vain We are looking for suitable partners to promote the company's listing." Ginkgolide injection is an effective part preparation of natural medicine, which can be widely used in the clinical treatment of ischemic stroke (stroke) There are more than 130 countries using ginkgolide preparation in the world, but only one hundred plus has unique neuroprotective effect and antiplatelet aggregation It took Baiyu group 11 years to extract effective substances from Ginkgo biloba leaves and develop ginkgolide injection The cost of research and development of the company each year reached 15% - 20% of the total sales Why does it take 11 years to develop this new drug? How much is its market value? It is understood that ginkgolide injection is an effective part preparation of natural medicine, which can be widely used in the treatment of ischemic stroke (stroke) in clinical Feng Jianhua, vice president of Bayu group and head of development and planning department, said that there are more than 130 countries using ginkgo biloba preparation in the world, but only Bayu has unique neuroprotective and antiplatelet aggregation effects, and most domestic products are German products at present, "market potential can be predicted" Behind the approval of ginkgolide injection, there is also a wave of twists and turns The technology has been mature for several years, and Baiyu group is ready to apply for approval, but in that year, China stopped the approval of all new drugs "At that time, I was somewhat discouraged because without the approval documents, the drugs could not be listed and the investment could not be realized." Feng Jianhua said However, Baiyu did not give up lightly, but practiced "internal skill" Feng Jianhua said that low content and unknown ingredients have always been the "bottleneck" of traditional Chinese medicine injections, so we have worked hard on these two aspects When it was opened for approval in 2011, Chengdu Baiyu ginkgolide injection achieved 100% clear ingredients and 99% effective ingredients, and successfully obtained the new drug certificate and production approval issued by the State Food and drug administration In that year, there were more than 1300 traditional Chinese medicine products applied with Baiyu, only two of which were approved Baiyu was one of them In the process of Baiyu's commitment to independent research and development, Chengdu new drug research and development funding and support funds for major scientific and technological achievements transformation projects of Chengdu's independent innovation have been put in place one after another "There are a lot of support from governments at all levels, with millions of yuan, which is of great significance for Baiyu to strengthen its research and development direction and enhance its research and development strength." "It is estimated that the domestic market of ginkgo products is expected to be 10 billion yuan." The huge market potential of Baiyu ginkgolide injection has also attracted the attention of the medical and capital circles When the products have not been approved, large pharmaceutical companies have already sold "olive branch" to Baiyu, and "there are 2 billion yuan for products, and 3 billion yuan for products." But Baiyu didn't accept it Feng Jianhua said, "we want to be an independent R & D enterprise in Chengdu, and we want to do our products well in Chengdu." After being approved, more enterprises will be found "Over the past year, we have received more than 200 VC institutions." "But it's not decided yet It's not that we don't want to introduce capital, but that we want to select partners who best understand the company's value and are willing to grow together," Feng said On December 22 of this year, the production project of ginkgolide injection with an investment of 660 million yuan was officially started in Chengdu high tech west zone It is expected that the construction period will be 24 months, and the production period can achieve 500 million injections / year for small volume injection and 100 million injections / year for freeze-dried powder injection, realizing an annual sales revenue of more than 5 billion yuan Chengdu Baiyu jingelei Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Baiyu group, is responsible for this project "This base aims to build new drugs that meet international standards, make ginkgolide injection go abroad and share the share of international market." Sun Yi told Chengdu Business Daily that the designer of the new base had participated in the factory design of Bayer, Germany, and the construction standard would meet the cGMP standards of the United States and the European Union and the GMP standards of China The base covers an area of about 80 mu, with a total construction area of about 100000 square meters, of which 8000 square meters are scientific research buildings and supporting facilities In Chengdu, where major industrial bases gather, it is not easy to take 80 mu of land at one stroke, which is mainly due to the great help of the high tech Zone "Only when the government believes in the R & D strength and market potential of Baiyu, can we get 80 mu of land for us under the background of land shortage." Sun Yi revealed that while building the production base, the company is also preparing to build a research institute with a scale of 500 people to further strengthen research and development At present, Chengdu Baiyu has nearly 100 R & D personnel It is expected that 15-20 new drugs and more than 20 invention patents will be applied for each year in the future Warmly celebrate the successful foundation ceremony of Chengdu Baiyu jingelei pharmaceutical new factory! Release time: December 22, 2013 browse times: 105 dream departure - warmly celebrate the successful foundation ceremony of Baiyu jingelei Pharmaceutical Co., Ltd on December 22, 2013, the foundation ceremony of the ginkgolide injection production project of Chengdu Baiyu jingelei Pharmaceutical Co., Ltd was successful The base is the second production base wholly invested and constructed by Baiyu group It is located in the West Park of Chengdu high tech Zone The planned investment of the project is RMB 660 million The planned construction period is 24 months When the production period is reached, it can achieve 500 million injections / year for small volume injection and 100 million injections / year for freeze-dried powder injection, realizing an annual sales revenue of more than 5 billion yuan Chengdu Baiyu jingelei Pharmaceutical Co., Ltd is a wholly-owned subsidiary invested by Baiyu group, with a registered capital of 100 million yuan Low content and unknown ingredients have always been the "bottleneck" of traditional Chinese medicine injections The ginkgolide injection independently developed by Baiyu for 11 years can be widely used in the clinical treatment of ischemic stroke, with 100% clear ingredients and 99% effective ingredients This is a truly modern and innovative natural drug injection with the milestone significance of internationalization of traditional Chinese medicine Sun Zong, chairman of the group, said that Baiyu will not only build a production base that conforms to the cGMP standards of the United States and the European Union and the GMP standards of China, but also adopt the internationally advanced production management concept to create new drugs that conform to the international standards, so as to let ginkgolide injection go out of the country and go to the world Ginkgolide injection is an effective part of natural medicine, which can be widely used in the treatment of ischemic stroke At present, there are more than 270 million patients with cardiovascular and cerebrovascular diseases in China The number of new cerebrovascular patients in China is 3 million every year, and 1.2-1.5 million people die of stroke every year The situation of prevention and treatment will be increasingly severe However, it is generally acknowledged that Ginkgo biloba has a high medicinal value, especially in the treatment of vascular sclerosis, brain dysfunction, mental decline and other stubborn diseases At present, there are more than 130 countries using ginkgo biloba preparation all over the world Bayu ginkgolide injection contains Ginkgo bilobalide (48%), ginkgo bilobalide abcj (52%), ginkgo bilobalide has a multi-channel key upstream target of neurovascular unit protection Ginkgo bilobalide abcj is the most valuable natural PAF receptor antagonist in clinical application, which can block PAF induced platelet aggregation and protect injured neurons Ginkgolide injection has unique neuroprotective effect and antiplatelet aggregation effect at the same time Through clinical research, ginkgolide injection can be used to treat the syndrome of phlegm and blood stasis blocking collaterals in ischemic stroke, which is helpful to improve the self-care ability and quality of life of stroke patients "Breakthroughs in scientific and technological innovation and good market expectations are inseparable from the company's long-term emphasis on independent innovation." Mr Sun, the group's director general, further disclosed that while building the production base, the company is also preparing to build a research institute with a scale of 500 people to further strengthen R & D in the next 5-10 years, the proportion of R & D expenses to sales revenue will be increased to 20% At present, Chengdu Baiyu devotes 15% of its sales revenue to R & D every year, with nearly 100 R & D technicians, and has successfully introduced high-level R & D leaders With the support of continuously strengthened R & D strength, the company has obtained 6 invention patents, and is applying for 4 international invention patents and 37 domestic invention patents Every year, there are 15-20 new drugs, 10-15 high-quality imitated products and more than 20 invention patents "Chengdu Baiyu has unique advantages in R & D and production of ginkgolide injection Not only because ginkgo is the "city tree" of Chengdu, Sichuan has rich ginkgo resources, more importantly, with the rapid development of biomedical industry in Chengdu in recent years, Chengdu high tech Zone is becoming the first choice for famous biomedical enterprises at home and abroad to settle in the West " "In the process of promoting three times of entrepreneurship, Chengdu hi tech Zone will adhere to the plan as the leader and the professional park as the carrier to promote the sustainable and healthy development of biomedical and biomedical engineering industries," said the relevant person in charge of Chengdu hi tech Zone Perspective of jingelei base along the street general aerial view of jingelei base music performance waiting for guests to enter